Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
1don MSN
We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback